Firebrick Pharma (ASX:FRE) received notice of allowance of Nasodine's COVID-19 patent in Mexico, according to a Friday filing with the Australian bourse.
The patent protects the use of Nasodine nasal spray and any other intranasal povidone-iodine preparations as a method of reducing the viral load of SARS-CoV-2 in the nose, the filing stated.
The patent is already granted in the US, Australia, and South Africa, with applications in other countries still pending.
Firebrick Pharma's shares were up nearly 2% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。